Key Points
- Septerna SVP Daniel Long sold 3,333 shares at an average price of $37.83, generating $126,087.39 and reducing his direct holdings by 3.34% to 96,412 shares.
- Septerna recently exceeded quarterly expectations, reporting an adjusted loss of $0.29 per share versus the estimated $0.43 loss and revenue of $26.75 million versus the $19.22 million consensus.
- Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus rating and an average price target of $52.44, while the stock recently opened at $36.80.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) SVP Daniel Long sold 3,333 shares of the firm's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company's stock, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Septerna Stock Performance
Shares of NASDAQ SEPN opened at $36.80 on Friday. Septerna, Inc. has a one year low of $13.67 and a one year high of $51.10. The firm has a market capitalization of $1.72 billion, a P/E ratio of -68.15 and a beta of 2.30. The company's fifty day moving average is $37.46 and its two-hundred day moving average is $31.15.
Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The business had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. On average, sell-side analysts forecast that Septerna, Inc. will post -1.41 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on SEPN shares. Guggenheim increased their target price on shares of Septerna from $45.00 to $51.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a report on Friday, July 17th. Wells Fargo & Company upped their price target on Septerna from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. HC Wainwright lifted their price objective on Septerna from $40.00 to $60.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Septerna currently has an average rating of "Moderate Buy" and an average target price of $52.44.
Check Out Our Latest Research Report on Septerna
Institutional Trading of Septerna
Several institutional investors and hedge funds have recently modified their holdings of the business. TRV GP V LLC acquired a new stake in shares of Septerna in the second quarter valued at approximately $208,160,143. TRV GP VI LLC acquired a new position in shares of Septerna during the 2nd quarter worth approximately $141,048,460. Goldman Sachs Group Inc. lifted its stake in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock valued at $75,698,000 after buying an additional 1,260,409 shares in the last quarter. BlackRock Inc. purchased a new stake in Septerna in the 2nd quarter valued at approximately $64,706,000. Finally, Vanguard Group Inc. grew its holdings in Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after buying an additional 104,394 shares during the last quarter.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
